Rubiadin-1-methyl ether

Overview

Rubiadin-1-methyl ether is an orally potent NF-κB p65 inhibitor and autophagy inhibitor. Rubiadin-1-methyl ether inhibits RANKL -induced phosphorylation and nuclear translocation of p65, suppresses BECN1 transcription, blocks LC3 conversion and autophagosome formation, thereby reducing the levels of BECN1 mRNA and Beclin1 protein. Rubiadin-1-methyl ether inhibits osteoclastogenesis, cell proliferation, macrophage M2 polarization and the TGF-β1 signaling pathway, and effectively alleviates pulmonary inflammation. Rubiadin-1-methyl ether is widely used in research on osteoporosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, acute lung injury and other related diseases.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Respiratory Inflammation | Products > Disease Areas > Mineral Metabolism | Products > Disease Areas > Acute Lung Injury | Products > Disease Areas > Osteoporosis | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > RANKL/RANK | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > TGF-β Receptor

Product Information

• Catalog No.: HY-N1956
• CAS No.: 7460-43-7
• Molecular Formula: C16H12O4
• Molecular Weight: 268.26
• Purity: 98.57%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source